New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
12:43 EDTMNTAMomenta Pharma petition for rehearing denied by Court of Appeals
Momenta Pharmaceuticals announced that the United States Court of Appeals for the Federal Circuit denied its request for a rehearing en banc to reconsider its three-judge panel opinion in the case of Momenta Pharmaceuticals vs. Amphastar Pharmaceuticals, Inc. The request for all active judges of the court to reconsider a panel decision, known as rehearing en banc, is only granted upon a majority vote. "We will continue to pursue our appellate options and we plan to file a petition for certiorari, asking the Supreme Court to review this case," said Craig Wheeler, president and CEO of Momenta.
News For MNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:18 EDTMNTAAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
08:10 EDTMNTAMomenta price target raised to $24 from $16 at Leerink
Subscribe for More Information
08:00 EDTMNTATeva patent loss should move management to acquire Mylan, says Cowen
Subscribe for More Information
07:46 EDTMNTAMomenta price target raised to $25 from $15 at Brean Capital
Brean Capital raised its price target on Momenta to $25 from $15 following yesterday's announcement of the approval of generic Copaxone. Brean Capital reiterated its Buy rating on Momenta shares.
April 16, 2015
15:40 EDTMNTAGeneric Copaxone approval a bit early but expected, says BMO Capital
BMO Capital believes FDA approval for Sandoz (NVS) and Momenta's (MNTA) generic 20mg Copaxone came slightly earlier than the market expected, but the firm added that the generic threat has been well expected. The firm added that it appears Mylanís (MYL) generic Copaxone hasn't been approved yet, leaving a "legitimate question" about why the FDA approved one generic and not the other. BMO thinks Teva's rate of conversion to the 40mg dose will help retain patients on the Copaxone franchise and it keeps an Outperform rating on Teva shares.
12:37 EDTMNTAMomenta confirms Glatopa approval, to receive $10M payment
Subscribe for More Information
12:35 EDTMNTASandoz receives FDA approval for Glatopa as generic competitor to Copaxone
Sandoz, a Novartis (NVS) company, announced the U.S. approval of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy. Glatopa, developed in collaboration with Momenta (MNTA) and produced entirely in the U.S., is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging features consistent with MS.
12:35 EDTMNTAFDA denies Teva attempt to block generic Copaxone
Subscribe for More Information
12:29 EDTMNTAMomenta jumps after FDA denies Teva petition to block generic Copaxone

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use